Childrens Memorial Hospital

Staff Information

Andrea Paras, MS
(Clinic coordinator, genetic counselor)
(312)227-6772
aparas@luriechildrens.org

Heather Bausell RD, LDN
(Metabolic dietician)
(312)227-6122
hbausell@luriechildrens.org

Katie Arduini, RD, LDN
(Metabolic dietician)
(312)227-6771
karduini@luriechildrens.org

Amanda Aspan, MS RD LDN
(Metabolic dietician)
(312)227-6768
aaspan@luriechildrens.org

Soo Shim, MS, LCSW
(social worker)
(312)227-3386
sshim@luriechildrens.org

Barbara Burton, MD
(clinic director, metabolic geneticist)
bburton@luriechildrens.org

Angela Dean
(administrative assistant, receives phe levels)
(312)227-6120

Rachel Katz, MSW, LSW
(Research Coordinator)
(312)227-6764
rkatz@luriechildrens.org

Email for diet records for the dietitians.
metabolicdieticians@luriechildrens.org

Clinic Address

225 E. Chicago Ave, Box #59
Chicago, IL 60611-2605

Genetics Phone: 312-227-6120
Genetic Fax: 312-227-9413

3rd floor of Lurie Children’s hospital at 225 E. Chicago Ave

Blood Spot Mailing Address

225 E. Chicago Ave, Box #59
Chicago, IL 60611-2605

Satellite Clinics

Children’s Memorial Hospital Westchester Clinic- (once/ mo.) 2301 Enterprise Drive
Westchester, IL
T 708.836.4800

Wednesday mornings Westchester outpatient facility – 3rd Wednesday of the month, full day

Education/outreach activities:

We are planning an afterhours grocery store tour at Lil’s Dietary shop (the low protein food store in Chicago). This will be held on Thursday August 20th (2015) from about 6:30-8pm. Details to follow.

Research activities:

We continue to recruit subjects at least 18 years of age into the Phase 3 study of the investigational drug pegvaliase ( formerly referred to as PEG-PAL) sponsored by Biomarin. It is likely that recruitment will cease within the next several months when the targeted enrollment has been reached. At that time, all enrolled subjects will be followed until the study is completed at which time the data will be analyzed and submitted to the FDA. We also continue to follow younger children enrolled in PKU-015, the study of the safety and efficacy of Kuvan in patients under six years of age, including subjects enrolled in the first year of life. Data from the first two years of the study have been published and show that the drug is safe in young children and works in the same way as it does in older individuals. Children will be monitored in the study for a total of 7 years to demonstrate that cognitive function is preserved in treated patients. We also have many patients enrolled in the registry referred to as PKU-DOS. This is a study that involves only entering information gathered during the course of routine PKU care into a central registry where it is combined anonymously with data from other clinics. There are over 1000 patients nationally in the registry, which is giving us important information about the long term effects of PKU on patients, as well as answering specific questions such as those related to the safety and efficacy of Kuvan during pregnancy.